Persistent asthma: disease control, resource utilisation and direct costs.
about
Why do patients with long-term conditions use unscheduled care? A qualitative literature reviewSmall airway dysfunction and bronchial asthma control : the state of the artArterial blood gas and spirometry parameters affect the length of stay in hospitalized asthmatic patientsADAM8: a new therapeutic target for asthmaTreating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a reviewEconomic burden of asthma: a systematic reviewImpact of patient characteristics, education and knowledge on emergency room visits in patients with asthma and COPD: a descriptive and correlative study.Recommendation for optimal management of severe refractory asthma.Implementation of GINA guidelines in Ho Chi Minh City: a model for Viet NamA cross-sectional study evaluating the relationship between cortisol suppression and asthma control in patients with difficult asthma.Improved asthma control in patients with severe, persistent allergic asthma after 12 months of nightly temperature-controlled laminar airflow: an observational study with retrospective comparisons.Asthma worsenings: approaches to prevention and management from the Asthma Worsenings Working GroupA review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthmaMild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations.An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.Asthma control score based on filled medication prescriptions: a validation study.The nature and influence of pharmaceutical industry involvement in asthma trials.Economic costs for adult asthmatics according to severity and control status in Korean tertiary hospitals.'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review.Costs of perennial allergic rhinitis and allergic asthma increase with severity and poor disease control.Direct costs of asthma in Brazil: a comparison between controlled and uncontrolled asthmatic patients.Asthma exacerbations: prevention is better than cure.Saving in medical costs by achieving guideline-based asthma symptom control: a population-based study.Impact of patient-related factors on asthma control.How appropriate is asthma therapy in general practice?Direct medical cost of asthma in Ankara, Turkey.Effect of a concomitant diagnosis of allergic rhinitis on asthma-related health care use by adults.Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists.Improvements in symptoms and quality of life following exercise training in older adults with moderate/severe persistent asthma.Asthma and allergy medication use and costs among pediatric primary care patients on asthma controller therapy
P2860
Q26823799-CAE145BD-D3F4-4D60-9A0D-6214DF067EFFQ28067594-3D1B7B97-9CAB-4580-8519-0230F4C7A1DAQ28393677-36462E8C-C330-4FF5-A6D2-C8BDA2CAFF07Q28590394-CAA9C302-1966-40EA-AC92-8E9BDB32C9D1Q30801642-9F1C8B94-0BAD-4EFC-B3C1-7DDA2BC11736Q33447966-A1E25F27-D3BC-4453-9E8E-C8A0EB44C16EQ33500680-46B7D6D6-21E5-4CAA-8816-FC8740110B96Q34620187-355BC601-4C36-4458-A5A1-D50E4EB00D8BQ35718806-8E4CA322-738C-432A-8F86-3269538F2DC6Q36024948-B6AB6246-1FC9-4E8D-A791-2CD918F5FC9AQ36239388-3E207182-B149-4832-ACEB-1B1657C47935Q36364500-BAF29EF1-34E9-4BD3-839A-320CE6D821F7Q36642971-54EF162A-F860-4313-A4B8-5E6A4E14E23FQ36825039-91EEEECE-6D23-4AEB-8501-3FF4872C9B61Q37150465-3D4D3951-2B81-4F83-8FA8-3954530A3370Q37192325-5C779700-CE4B-4EE2-BFF6-E1994AE65ED4Q38034512-316D4263-694B-4800-873A-38E168DCB36BQ38467261-8AA0276A-9F2B-416D-8953-C2379724BC90Q38661772-C44A3DF4-9659-429D-9185-9668E07070B7Q39154275-DF2BA308-B7E4-40F9-A206-F00A550E813EQ39332620-49097CA7-C4DD-419B-AF33-93CBB0EAA16EQ39887730-8FA5499F-5BB1-4465-AA3F-EFA517A0E444Q41154590-C1379D84-DADC-464D-8B77-5395FF60567FQ44789417-60922978-2961-4221-91B0-2027244E70D7Q45231382-21759046-2F99-4738-AF8D-D3E0AAEAD7EFQ47871932-965A130A-918A-4FA5-AE19-02F21BE48680Q50758903-6F073C1B-15EF-469A-A64F-E16C9934282EQ51713924-1D98D7A1-9989-4BBF-A4C8-B6365B2982AAQ53074893-D42C73A0-7362-41CF-BA21-A6358B0D3008Q57746548-E3EC3BA9-67C1-48B9-8005-6DDD0418B672
P2860
Persistent asthma: disease control, resource utilisation and direct costs.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Persistent asthma: disease control, resource utilisation and direct costs.
@ast
Persistent asthma: disease control, resource utilisation and direct costs.
@en
Persistent asthma: disease control, resource utilisation and direct costs.
@nl
type
label
Persistent asthma: disease control, resource utilisation and direct costs.
@ast
Persistent asthma: disease control, resource utilisation and direct costs.
@en
Persistent asthma: disease control, resource utilisation and direct costs.
@nl
prefLabel
Persistent asthma: disease control, resource utilisation and direct costs.
@ast
Persistent asthma: disease control, resource utilisation and direct costs.
@en
Persistent asthma: disease control, resource utilisation and direct costs.
@nl
P2093
P1476
Persistent asthma: disease control, resource utilisation and direct costs.
@en
P2093
E Van Ganse
J P Boissel
L Laforest
R Ben-Joseph
P304
P356
10.1183/09031936.02.02542001
P577
2002-08-01T00:00:00Z